

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Colitis; inflammatory bowel disease (IBD)	Apolipoprotein E (APOE)	<p>Studies in mice suggest that the APOE mimetic peptide COG112 could help treat colitis and other forms of IBD. In two mouse models of colitis, COG112 decreased the severity of disease symptoms compared with saline control. Next steps include submitting an IND and obtaining funding for a clinical trial.</p> <p>COG112, an APOE mimetic peptide from Cognosci Inc., is in preclinical development to treat multiple sclerosis (MS).</p> <p>SciBX 3(48); doi:10.1038/scibx.2010.1455 Published online Dec. 16, 2010</p>	<p>Multiple patents pending covering COG112 and methods of use; available for licensing from Cognosci</p> <p>Contact: Michael Vitek, Cognosci Inc., Research Triangle Park, N.C. e-mail: mikevitek@cognosci.com</p>	<p>Singh, K. <i>et al.</i> <i>J. Biol. Chem.</i>; published online Nov. 29, 2010; doi:10.1074/jbc.M110.176719</p> <p>Contact: Keith T. Wilson, Vanderbilt University School of Medicine, Nashville, Tenn. e-mail: keith.wilson@vanderbilt.edu</p>